EUVIMEDAvasta EUVIMED
Open access

Small molecule tyrosine kinase inhibitors in pancreatic cancer

Sachin Gupta, Bassel F El-Rayes

Biologics: Targets & Therapy · 2008-10 · 707

DOI: 10.2147/btt.s3003 ↗

At a glance

Journal article in Biologics: Targets & Therapy, 2008-10. Written by Sachin Gupta and 1 co-authors. Institution: Department of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USA. Cited 8 times so far (Crossref). The full text is freely available in PubMed Central.

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for advanced pancreatic cancer since 1996. Tyrosine kinase inhibitors represent a newer generation of chemotherapeutic agents targeting specific tumor pathways associated with carcinogenesis including cell cycle control, signal transduction, apoptosis and angiogenesis. These agents present a more selective way of treating pancreatic cancer. Erlotinib is the prototype of the tyrosine kinase inhibitors with proven efficacy in advanced pancreatic cancer and has been recently approved in that setting. Multiple other tyrosine kinase inhibitors targeting the VEGFR, PDGFR, and Src kinases are in various phases of clinical trials testing. The preliminary results of these trials have been disappointing. Current challenges in pancreatic cancer clinical trials testing include improving patient selection, identifying effective combinations, improving the predictive value of current preclinical models and better study designs. This review summarizes the present clinical development of tyrosine kinase inhibitors in pancreatic cancer and strategies for future drug development.

Subjects

Author keywords

erlotinibpancreatic cancertyrosine kinase inhibitors

Authors and institutions

  • Department of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USA.

Cite

APA

Gupta, S., & El-Rayes, B. F. (2008). Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics: Targets & Therapy, 707. https://doi.org/10.2147/btt.s3003

Vancouver

Gupta S, El-Rayes BF. Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics: Targets & Therapy. 2008:707. doi:10.2147/btt.s3003

BibTeX
@article{Gupta2008,
  author = {Gupta, Sachin and El-Rayes, Bassel F},
  title = {Small molecule tyrosine kinase inhibitors in pancreatic cancer},
  journal = {Biologics: Targets & Therapy},
  year = {2008},
  pages = {707},
  doi = {10.2147/btt.s3003}
}
Start for free →